These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16798000)

  • 1. Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents.
    Hamad MO; Kiptoo PK; Stinchcomb AL; Crooks PA
    Bioorg Med Chem; 2006 Oct; 14(20):7051-61. PubMed ID: 16798000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion.
    Kiptoo PK; Hamad MO; Crooks PA; Stinchcomb AL
    J Control Release; 2006 Jun; 113(2):137-45. PubMed ID: 16750868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.
    Kiptoo PK; Paudel KS; Hammell DC; Hamad MO; Crooks PA; Stinchcomb AL
    Eur J Pharm Sci; 2008 Apr; 33(4-5):371-9. PubMed ID: 18321686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
    Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
    Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.
    Ghosh P; Lee D; Kim KB; Stinchcomb AL
    Pharm Res; 2014 Jan; 31(1):148-59. PubMed ID: 23943543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo.
    Paudel KS; Nalluri BN; Hammell DC; Valiveti S; Kiptoo P; Hamad MO; Crooks PA; Stinchcomb AL
    J Pharm Sci; 2005 Sep; 94(9):1965-75. PubMed ID: 16052561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
    Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
    Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
    Banks SL; Pinninti RR; Gill HS; Crooks PA; Prausnitz MR; Stinchcomb AL
    Pharm Res; 2008 Jul; 25(7):1677-85. PubMed ID: 18449628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
    O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
    J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology.
    Imaide S; Fujii H; Watanabe A; Nemoto T; Nakajima M; Nakao K; Mochizuki H; Nagase H
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1055-8. PubMed ID: 20056539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcohol consumption is enhanced after naltrexone treatment.
    Juárez J; Eliana Bde T
    Alcohol Clin Exp Res; 2007 Feb; 31(2):260-4. PubMed ID: 17250617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective analysis of hydroxybupropion and application to drug interaction studies.
    Xu H; Loboz KK; Gross AS; McLachlan AJ
    Chirality; 2007 Mar; 19(3):163-70. PubMed ID: 17167747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma.
    Clavijo C; Bendrick-Peart J; Zhang YL; Johnson G; Gasparic A; Christians U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):33-41. PubMed ID: 18805072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The codrug approach for facilitating drug delivery and bioactivity.
    Aljuffali IA; Lin CF; Chen CH; Fang JY
    Expert Opin Drug Deliv; 2016 Sep; 13(9):1311-25. PubMed ID: 27159251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
    Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
    J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction.
    Fujii H; Osa Y; Ishihara M; Hanamura S; Nemoto T; Nakajima M; Hasebe K; Mochizuki H; Nagase H
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4978-81. PubMed ID: 18755589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbon-13 nuclear magnetic resonance identification of 2-hydroxy-3-O-methyl-6beta-naltrexol as a minor naltrexone metabolite.
    Brine GA; Brine DR; Welch CD; Bondeson VC; Carroll FI
    Res Commun Chem Pathol Pharmacol; 1978 Dec; 22(3):455-64. PubMed ID: 734225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent.
    Hammell DC; Stolarczyk EI; Klausner M; Hamad MO; Crooks PA; Stinchcomb AL
    J Pharm Sci; 2005 Apr; 94(4):828-36. PubMed ID: 15736197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.